Tue, Sep 16, 2014, 12:28 AM EDT - U.S. Markets open in 9 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

  • stemcellmagnet stemcellmagnet Sep 17, 2013 5:38 PM Flag

    Dermagraft got crushed down 57%

    Majority of top ten products deliver double digit growth
    Q2 2013 Q2 2012 $m$m$m
    Reported Growth
    CER Growth % %
    +13% +13% +22% +25% +46% +46%
    -7% -5% +31% +31% - +1% +15% +15% +56% +56% -57% -57% -9% -8% +10% +11% -16% -16% +7% +8%
    VYVANSE 300
    ELAPRASE 149
    LIALDA / MEZAVANT 138 94 44
    REPLAGAL 114 INTUNIV 90 VPRIV 83 PENTASA

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Growth in total product sales was moderated by DERMAGRAFT® (down 57% to $22 million), ADDERALL XR® (down 16% to $112 million) and REPLAGAL® (down 7% to $114 million; down 5% on a CER basis). Q2 2013 sales for all three products compare against strong prior year comparatives that will ease over the second half of the year.

 
MDXG
6.92-0.30(-4.16%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT